Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 sept. 2019 17h00 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
26 sept. 2019 08h30 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Presentations at IDWeek 2019

CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
08 août 2019 16h10 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update

CAMBRIDGE, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
31 mai 2019 17h00 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
09 mai 2019 16h10 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review

CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
01 mai 2019 08h00 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
08 avr. 2019 08h30 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases

CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
29 mars 2019 08h00 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis

CAMBRIDGE, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
19 mars 2019 08h00 HE | Source: Spero Therapeutics, Inc.

Spero Announces Appointment of Cynthia Smith to its Board of Directors

CAMBRIDGE, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
01 mars 2019 08h30 HE | Source: Spero Therapeutics, Inc.

Spero Therapeutics to Present at March Investor Conferences

CAMBRIDGE, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...

Page suivante